KUVOVDA
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

KUVOVDA Trademark

Serial Number: 50045963

KUVOVDA is a trademark filed by Hong Kong King-Friend, Industrial Company, Ltd. on August 12, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Hong Kong King-Friend, Industrial Company, Ltd. (7 trademarks)

Room 2808, 28/F Omega Plaza, 32 Dundas St.
Hong Kong , HK

Entity Type: 16

Trademark Details

Filing Date

August 12, 2026

Registration Date

Not Registered

Goods & Services

Providing medical information; providing health information; providing medical information in the field of cancer and cancer treatments; providing health information in the field of cancer and cancer treatmentsiabetes; medical and pharmaceutical consultation; pharmaceutical advice; providing information to patients in the field of administering medications; individual medical counseling services provided to patients; providing personal support services for families of patients with life threatening disorders, namely, health counseling services

Providing information in the field of scientific and medical research related to pharmaceuticals; providing information in the field of scientific and medical research related to cancer and cancer treatments; research and development of pharmaceuticals; research and development of pharmaceuticals in the field of cancer and cancer treatments

Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; biologics; biosimilars; pegfilgrastim biosimilars; pharmaceutical preparations for the treatment of neutropenia; pharmaceutical preparations for the treatment of low white blood cells; pharmaceutical preparations for use in stimulating white blood cell production; biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production; recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable pegfilgrastim biosimilars; pharmaceutical preparations, namely, injectable biosimilars for the treatment of neutropenia; pharmaceutical preparations, namely, injectable biosimilars for the treatment of low white blood cells; pharmaceutical preparations, namely, injectable biosimilars for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable recombinant-human granulocyte-CSF for use in stimulating white blood cell production; pharmaceutical preparations, namely, injectable recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production; injectors sold filled with pegfilgrastim biosimilars; injectors sold filled with pharmaceutical preparations for the treatment of neutropenia; injectors sold filled with pharmaceutical preparations for the treatment of low white blood cells; injectors sold filled with pharmaceutical preparations for use in stimulating white blood cell production; injectors sold filled with biosimilars for use in stimulating white blood cell production; injectors sold filled with recombinant-human granulocyte-CSF for use in stimulating white blood cell production; injectors sold filled with recombinant-human granulocyte-CSF biosimilars for use in stimulating white blood cell production

Filing History

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 12, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Aug 12, 2026 MAFR
NEW APPLICATION ENTERED
Aug 12, 2026 NWAP